This site is intended for health professionals only

Published on 25 November 2008

Share this story:

Drug “rivals nets” in malaria fight


A malaria drug treatment may be almost as effective as bug-deadly mosquito nets in preventing the disease in less prevalent areas, according to a study.

Experts from the London School of Hygiene & Tropical Medicine used mathematical modelling to predict the outcome of using artemisinin combination therapies (ACTs) as a first-line treatment for uncomplicated malaria.

The study, published in the journal PLoS Medicine, estimated the effects of ACT from clinical trial data. It showed that in low-transmission areas, a 53% decrease in clinical episodes would occur if all current treatments were switched to ACT – in line with figures relating to the effectiveness of insecticide-treated nets (ITNs). This compared to 21% in the areas with the highest transmission.

In high transmission areas, long-acting antimalarial regimens may be needed to achieve significant transmission reductions, the study said.

Lead author Lucy Okell, of the London School of Hygiene & Tropical Medicine, said: “Overall, we predict that at existing treatment rates, a 100% switch to ACT from nonartemisinin drugs could reduce the rate of clinical episodes of malaria by between 21% and 53% if a short-acting ACT such as artemether-lumefantrine was used.

“As endemic countries gear up for malaria eradication, a target called for by the Bill and Melinda Gates Foundation in 2007, it will be important to know how choice of first-line treatment can help reach this goal’.”

Copyright Press Association 2008

PLoS Medicine

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: